Stakeholders in medical devices sector urged by CDSCO to ensure timely payment of retention fees to maintain validity of licenses and certificates
The Central Drugs Standard Control Organisation (“CDSCO”) has reiterated that licenses for... Read More
CDSCO allows operational continuity for importers and manufacturers of Class C & D Medical Devices; pending pre-September 2023 licensing applications deemed valid until 16th August, 2024 or CLA decision
The Central Drugs Standard Control Organization (CDSCO) has issued a Circular in response to... Read More
NOC for manufacture of unapproved/approved new drugs/banned drugs (solely for export) to be obtained from Zonal offices via Sugam Portal, effective from 15th May 2024: CDSCO
The Central Drugs Control Standards Organization (CDSCO) has communicated to drug controllers of... Read More
Public comments invited till 25th April, 2024 on draft of revised guidance for industry to align with the New Drugs and Clinical Trials (NDCT) Rules, 2019 and Sugam application process (Version 1.2)
With a view to align the submission procedure of clinical trial application (as prescribed under... Read More